BeiGene, Ltd.

Submit Your Information

Company Name	BeiGene, Ltd.
Stock Symbol	BGNE
Status	1

On September 5, 2019, J Capital Research published a report alleging, among other things, that BeiGene “is faking sales in order to persuade investors that it can develop a successful platform in China” and that “management may also be skimming R&D and capital budgets.”

On this news, BeiGene’s American depositary receipt price fell $19.95 per share, or 14.19%, over the following two trading sessions to close at $120.61 on September 6, 2019, thereby injuring investors.

Submit Your Information

If you suffered a loss on your BeiGene, Ltd. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

First Name*

Middle Initial

Last Name*

Email*

Phone*

If representing a Corporation, Trust, Partnership or other entity, Name of Entity

If representing an Entity, Position at Entity

Mailing Address

City

State/Province

ZIP/Postal Code

Country

Are you a current or former employee of the company?

Did you purchase any shares before January 01, 1970?

Shares Purchased

Number of Shares	Buy Date	Price Per Share	Add
Purchased quantity	Purchased month Purchased day Purchased year

Shares Sold

Number of Shares	Sell Date	Price Per Share	Add
	Sold month Sold day Sold year

Additional Comments